• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves next-gen intrathecal drug delivery system from Medtronic

October 10, 2023 By Sean Whooley

Medtronic SynchroMed III drug delivery system
The SynchroMed III system. [Image courtesy of Medtronic]
Medtronic (NYSE:MDT) announced today that the FDA approved its next-generation SynchroMed III intrathecal drug delivery system.

The medtech giant designed SynchroMed III to treat patients with chronic pain, cancer pain and severe spasticity. The targeted drug delivery (TDD) system alleviates symptoms by delivering medication directly to the fluid surrounding the spinal cord.

SynchroMed III builds upon the previous SynchroMed II system, featuring a new “refill only” physician workflow. This enables more efficient programming, while improved electronics feature firmware capable of updates post-implant. Additionally, the system has other protections for patient data through enhanced cybersecurity.

Medtronic said its system also carries forward several mid-generation durable design enhancements from the previous generation.

The system delivers fluid via a catheter connected to a small, battery-powered programmable pump. Patients with the pump can continue accessing diagnostic imaging through Medtronic’s 1.5T and 3T full-body MRI conditionality.

SynchroMed III can work with the company’s Control Workflow, which helps to eliminate the use of systemic opioids by certain patients. The framework can be tailored to individual patients and it assists physicians in identifying patients likely to have positive outcomes.

Control Workflow supports oral opioid tapering and drug holidays, allowing for treatment with the lowest effective doses. This can improve pain relief compared to a combination of oral and intrathecal treatment.

Medtronic plans to make SynchroMed III commercially available later this calendar year.

“Medtronic has offered targeted drug delivery therapy for over 30 years, and we continue to further enhance this technology,” said David Carr, VP and GM, Pain Interventions within the Neuromodulation business at Medtronic. “The SynchroMed III system brings forward several important developments and represents another step forward in our commitment to delivering solutions that alleviate pain and improve lives through innovative medical technology.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Regulatory/Compliance Tagged With: FDA, Medtronic

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS